Related Experiment Video
Updated: May 28, 2026
11:25
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
Fludarabine versus chlorambucil: is the debate over?
Kanti R Rai1, Angelica Hollweg
1Long Island Jewish Medical Center, Hofstra University School of Medicine, New York, NY 11042, USA. krai@nshs.edu
Clinical Lymphoma, Myeloma & Leukemia
|November 1, 2011
Summary
Fludarabine is now the superior choice for initial chronic lymphocytic leukemia (CLL) treatment, replacing chlorambucil. Long-term follow-up shows fludarabine significantly improves overall survival in CLL patients.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Background:
- Chlorambucil was the standard first-line treatment for chronic lymphocytic leukemia (CLL) from the 1950s to the 1990s.
- Fludarabine emerged in the 1990s, becoming a preferred therapeutic agent for CLL treatment.
Purpose of the Study:
- To compare the efficacy of fludarabine versus chlorambucil in the initial treatment of chronic lymphocytic leukemia (CLL).
- To evaluate the long-term survival outcomes of fludarabine and chlorambucil in front-line CLL therapy.
Main Methods:
- Prospective, randomized clinical trials were conducted comparing fludarabine and chlorambucil for front-line CLL therapy.
- Long-term follow-up data from these trials were analyzed to assess overall survival.
Main Results:
- Initial trials showed fludarabine significantly increased complete remission, overall remission rates, and progression-free survival compared to chlorambucil.
- A long-term follow-up revealed a significant improvement in overall survival for patients initially randomized to fludarabine, apparent after approximately six years.
Conclusions:
- Fludarabine has demonstrated superiority over chlorambucil for the initial treatment of chronic lymphocytic leukemia (CLL).
- The long-term survival benefit of fludarabine in CLL treatment becomes evident over extended follow-up periods.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...